Main Role Of Morphogenetic Between Fgf-23 And Sklotho In The Development Of Herdic And Vasicular Models In Chronic Key Disease Patients
Keywords:
Abstract
Diabetes is a major cause of chronic kidney disease (CKD). Poor blood sugar control accelerates the progression of CKD to terminal renal failure. Chronic kidney disease is also an important co-morbidity of diabetes. Impaired renal function further increases the risk of cardiovascular events in diabetic patients and ultimately carries a severe social and economic burden. Altered fibroblast growth factor 23 (FGF-23) and Klotho levels are considered the earliest biochemical abnormality of chronic kidney disease, the mineral and bone disease syndrome.
Similar Articles
-
Comparative Characteristics Of The Morphological Parameters Of The Liver At Different Periods Of Traumatic Brain Injury
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2021) / Jumaev B. B, Klichev U. N, Pirboev F. M, -
FORENSIC EVALUATION OF DIFFUSE AXONAL INJURY
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2022) / Iskandarov Alisher Iskandarovich , Yakubov Khayot Hamidullaevich , Ismatov Abrorkhon Askarovich , -
DIFFERENTIATED HYPEROSMOLARY THERAPY IN CEREBRAL EDEMA IN PATIENTS WITH CRANIOCEREBRAL INJURY
The American Journal of Medical Sciences and Pharmaceutical Research: No. 11 (2023) / Murotov Temur Malik Nizomovich, Mi'rzambetov Dastan Qi'uani'shbaevich, -
Damage To Eyes, Orbit And Visual Nerve , Combined With Cranial Injury In Emergency Medicine
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2021) / Yorkinoy Turaeva, Bakhtiyor Urinboev, Nurillo Sobirov, Oblayer Abdullaev, -
Characteristic Of The Morphometric Parameters Of The Liver In Polypragmasia
The American Journal of Medical Sciences and Pharmaceutical Research: No. 10 (2021) / Usanov Sanat Sadinovich, -
Features Of Anemia In Patients With Chronic Liver Diseases
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2021) / Ismatova Mehriniso Nasritdinovna , Mukhammedzhanova Mastura Hayatovna , -
The Course Of Chronic Liver Disease In Patients With Covid-2019 (Literature Review And Own Data)
-
Laboratory And Molecular-Genetic Markers Of The Progression Of Non-Alcoholic Fatty Liver Disease (literature review and own data)
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2021) / Hamrayev A.A., Yuldasheva D.H., -
BIOCHEMICAL CHANGES OF CHRONIC GENERALIZED PERIODONTITIS IN CHRONIC VIRAL HEPATITIS B, C AND MIXED INFECTIONS
The American Journal of Medical Sciences and Pharmaceutical Research: No. 08 (2023) / Nazarova Nodira Sharipovna, Shukurov Sherzod Shukhratovich, -
TEMPORAL ANALYSIS OF THE PREVALENCE OF OSTEOARTICULAR PAIN AND MENTAL HEALTH
The American Journal of Medical Sciences and Pharmaceutical Research: No. 11 (2023) / Melissa Alves Aires Marques, Bianca Gabriella De Oliveira, Allan Rodrigues Corsini, Cícero Azevedo De Moraes Filho, Paloma Pinheiro De Aquino Peixoto, Fabricio Negreiros Holtz, Rafael Costa Nerys, Laís Cristina Pereira Da Silva, Marcella Rodrigues Costa Simoes,
References
McCullough P.A., Assad H. Diagnosis of cardiovascular disease in patien
ts with chronic kidney disease//Blood. Purif. – 2012. – Vol. 33(1-3). – P. 112-118.
. Моисеев В.С., Мухин Н.А., Смирнов А.В. и соавт. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции//Российский кардиологический журнал. – 2014. - № 8. – С.7-37.
. Mendoza J.M., Isakova T., Cai X., Bayes L.Y., Faul C., Scialla J. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease // Kidney Int. – 2017. – V. 91. – I.3. – P. 711-719.
. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. – 2004. –Vol. 351. – P. 1296–1305 [PubMed]
. Foley R., Murray A.M., Li S. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999//J. Наукаожизнииздоровье №2, 2019 34 Am. Soc. Nephrol. – 2005. – Vol. 16 (2). – P. 489 – 495.
. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am SocNephrol. 2005; 16(2):520–528.
. McGovern A.P., de Lusignan S., van Vlymen J. et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013; 8(9): e74996
. Kendrick J., KestenbaumВ. ChoncholМ. Phosphate and cardiovascular disease. Adv Chronic Kidney Dis. 2011; 18 (2):113 – 119.
Moe S.М. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) / Moe S., Drueke T., Cunningham J. et al. // Kidney Int. – 2006. – Vol. 69. – P. 945-1953.
